Quick Answer
BioXcel Therapeutics, Inc. reported Long-Term Debt of $84.66 million for fiscal year 2025.
BioXcel Therapeutics, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $84.66M | -17.4% |
| 2024 | $102.51M | +1.9% |
| 2023 | $100.60M | +8.1% |
| 2022 | $93.05M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $92.30M | -11.6% | -5.3% |
| June 30, 2025 | $97.47M | -5.4% | -2.5% |
| March 31, 2025 | $99.92M | -1.7% | -2.5% |
| December 31, 2024 | $102.51M | +1.9% | -1.8% |
| September 30, 2024 | $104.44M | +5.4% | +1.4% |
| June 30, 2024 | $103.01M | +6.4% | +1.4% |
| March 31, 2024 | $101.63M | +6.9% | +1.0% |
| December 31, 2023 | $100.60M | +8.1% | +1.5% |
- BioXcel Therapeutics, Inc. showed a decrease of -17.4% in Long-Term Debt compared to the prior fiscal year.
- Over the 2022–2025 period, BioXcel Therapeutics, Inc.’s long-term debt has declined by 9.0% (from $93.05 million to $84.66 million).
- The most recent figure is from BioXcel Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: